These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 27250222)

  • 1. [The prevalence of dementia in subacute myelo-optico-neuropathy (SMON) patients who underwent medical checkups].
    Saito Y; Sakai K; Konagaya M
    Nihon Ronen Igakkai Zasshi; 2016; 53(2):152-7. PubMed ID: 27250222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physical Disabilities Related to the Depressive Mental States of Japanese Patients with Subacute Myelo-optico-neuropathy.
    Konishi T
    Intern Med; 2018 Sep; 57(18):2641-2645. PubMed ID: 29780125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Aggravation of Depression with Aging in Japanese Patients with Subacute Myelo-optico-neuropathy (SMON).
    Konishi T; Hayashi K; Sugiyama H
    Intern Med; 2017 Aug; 56(16):2119-2123. PubMed ID: 28781313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sleep problems in subacute myelo-optico neuropathy (SMON).
    Hishikawa N; Takemoto M; Sato K; Yamashita T; Ohta Y; Sakai K; Abe K
    J Clin Neurosci; 2019 Oct; 68():128-133. PubMed ID: 31326286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depression in patients with subacute myelo-optico-neuropathy (SMON).
    Konishi T; Hayashi K; Hayashi M; Ueno S; Yoshida S; Fujimura H; Funakawa I; Kaido M
    Intern Med; 2008; 47(24):2127-31. PubMed ID: 19075537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tongue strength in patients with subacute myelo-optico-neuropathy.
    Yamashita S; Nakama T; Ueda M; Honda S; Kimura E; Konagaya M; Ando Y
    J Clin Neurosci; 2018 Jan; 47():84-88. PubMed ID: 29054330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [SMON: toxicity of clioquinol and the status quo].
    Konagaya M
    Brain Nerve; 2015 Jan; 67(1):49-62. PubMed ID: 25585435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [SMON--a model of the iatrogenic disease].
    Takasu T
    Rinsho Shinkeigaku; 2003 Nov; 43(11):866-9. PubMed ID: 15152488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Founder genetic variants of ABCC4 and ABCC11 in the Japanese population are not associated with the development of subacute myelo-optico-neuropathy (SMON).
    Matsumoto H; Sasai H; Kawamoto N; Katsuyama M; Minamiyama M; Kuru S; Fukao T; Ohnishi H;
    Mol Genet Genomic Med; 2022 Jan; 10(1):e1845. PubMed ID: 34951141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cervical MRI of subacute myelo-optico-neuropathy.
    Kimura E; Hirano T; Yamashita S; Hirai T; Uchida Y; Maeda Y; Uchino M
    Spinal Cord; 2011 Feb; 49(2):182-5. PubMed ID: 20548321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss-of-function polymorphisms in NQO1 are not associated with the development of subacute myelo-optico-neuropathy.
    Matsumoto H; Sasai H; Kawamoto N; Katsuyama M; Minamiyama M; Kuru S; Fukao T; Ohnishi H;
    Mol Genet Genomic Med; 2024 Jun; 12(6):e2470. PubMed ID: 38860482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Fifity years after the identification of the cause of SMON].
    Kuru S
    Rinsho Shinkeigaku; 2021 Feb; 61(2):109-114. PubMed ID: 33504748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical analysis of longstanding subacute myelo-optico-neuropathy: sequelae of clioquinol at 32 years after its ban.
    Konagaya M; Matsumoto A; Takase S; Mizutani T; Sobue G; Konishi T; Hayabara T; Iwashita H; Ujihira T; Miyata K; Matsuoka Y
    J Neurol Sci; 2004 Mar; 218(1-2):85-90. PubMed ID: 14759638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Subsets of peripheral blood lymphocytes and ageing in patients with SMON].
    Matsuda M; Yanagisawa N; Tsukada N
    Arerugi; 1991 Sep; 40(9):1226-31. PubMed ID: 1835574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subacute myelo-optico-neuropathy (SMON) in Japan. With special reference to the autopsy cases.
    Egashira Y; Matsuyama H
    Acta Pathol Jpn; 1982; 32 Suppl 1():101-16. PubMed ID: 6316716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SMON as seen from Bombay.
    Wadia NH
    Acta Neurol Scand Suppl; 1984; 100():159-64. PubMed ID: 6091394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of neurological symptoms related to hip fracture in a 29-year longitudinal study of subacute myelo-optic-neuropathy (SMON)].
    Konagaya M; Kuru S; Konagaya Y
    Nihon Ronen Igakkai Zasshi; 2010; 47(5):445-51. PubMed ID: 21116089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subacute myelo-optico-neuropathy: clioquinol intoxication in humans and animals.
    Tateishi J
    Neuropathology; 2000 Sep; 20 Suppl():S20-4. PubMed ID: 11037182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subacute myelo-optic neuropathy and clioquinol. An epidemiological case-history for diagnosis.
    Meade TW
    Br J Prev Soc Med; 1975 Sep; 29(3):157-69. PubMed ID: 127638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current perception threshold in subacute myelo-optico-neuropathy.
    Suzuki Y; Ogawa K; Shiota H; Kamei S; Oishi M; Mizutani T
    Int J Neurosci; 2010 May; 120(5):368-71. PubMed ID: 20402576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.